How to Prescribe Famotidine
For adults with normal renal function, prescribe famotidine 20 mg twice daily or 40 mg once daily for most indications, with dose adjustments required for moderate-to-severe renal impairment (creatinine clearance <60 mL/min). 1
Adult Dosing by Indication
Standard dosing regimens (for patients ≥40 kg with normal renal function) 1:
- Active duodenal ulcer: 40 mg once daily OR 20 mg twice daily for up to 8 weeks (most patients heal within 4 weeks)
- Active gastric ulcer: 40 mg once daily for up to 8 weeks
- Symptomatic non-erosive GERD: 20 mg twice daily for up to 6 weeks
- Erosive esophagitis: 20 mg twice daily OR 40 mg twice daily for up to 12 weeks
- Pathological hypersecretory conditions: Start 20 mg every 6 hours, adjust to patient needs (maximum 160 mg every 6 hours)
- Duodenal ulcer recurrence prevention: 20 mg once daily for 1 year
Pediatric Dosing
For children ≥1 year weighing ≥40 kg: Use adult dosing (20-40 mg tablets) 1
For children 1-16 years weighing <40 kg: 1 mg/kg/day divided in 2 doses (use oral suspension formulation, not tablets) 2
For infants <1 year: The 20 mg and 40 mg tablet formulations are not appropriate. Research demonstrates that infants have prolonged elimination half-lives and reduced clearance compared to older children 3, 4. Dosing must be weight-based using liquid formulations, with particular caution in neonates who show significantly altered pharmacokinetics.
Renal Dose Adjustments
Critical adjustment required - famotidine is 65-70% renally eliminated 1:
Moderate renal impairment (CrCl 30-60 mL/min) 1:
- Active ulcers/GERD: 20 mg once daily OR 40 mg every other day
- Erosive esophagitis: 20 mg once daily OR 40 mg every other day
Severe renal impairment (CrCl <30 mL/min) 1:
- All indications: 20 mg every other day (or 10 mg once daily using alternate formulation)
- Avoid use for pathological hypersecretory conditions (doses required exceed safe limits in renal impairment)
The pharmacokinetic data are compelling: AUC increases at least 2-fold with moderate impairment and at least 5-fold with severe impairment 1. Pediatric data confirm this relationship holds across age groups 5.
Administration Instructions
- Timing: Once daily dosing should be given at bedtime; twice daily dosing in morning and at bedtime 1
- Food: May take with or without food (food may improve GI tolerability but doesn't significantly affect absorption) 1
- Antacids: Can be given concurrently with antacids 1
- Route: Oral tablets or oral suspension; IV formulation exists but oral is preferred when feasible
Critical Care Context
For stress ulcer prophylaxis in ICU patients, use low-dose famotidine (≤40 mg daily) 6. The guideline emphasizes that H2-receptor antagonists like famotidine are less effective than PPIs for preventing clinically important upper GI bleeding but may have lower mortality risk. However, H2RAs develop tachyphylaxis within 6 weeks, limiting long-term effectiveness 2.
Common Pitfalls to Avoid
Failure to adjust for renal function: This is the most critical error. Always calculate creatinine clearance before prescribing 1, 5
Using tablet formulations in young children: The 20 mg tablet exceeds recommended doses for children <40 kg; use oral suspension instead 1
Expecting sustained efficacy with IV use: Research shows that repeated IV dosing leads to decreased duration of effect, with second doses maintaining pH >4 for only 6.9 hours versus 14.9 hours after first dose 7
Overlooking drug interactions: Famotidine is a substrate for OAT1 and OAT3 transporters; probenecid increases famotidine exposure significantly 1
Inadequate monitoring in elderly: Patients >65 years often have reduced renal function even with "normal" creatinine; dose reduction may be necessary 1
Special Populations
Elderly patients: No specific dose reduction based on age alone, but assess renal function carefully as it declines with age 1
End-stage renal disease: Most patients tolerate 20 mg daily, but approximately 8% may develop mental status changes requiring further dose reduction 8
Infants <3 months: Significantly prolonged half-life (10.51 hours vs 2.5-3.5 hours in adults) and reduced clearance necessitate careful dosing if used 4